Side-by-side · Research reference
AdipotidevsMT-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BFDA-ApprovedHUMAN-REVIEWED9/51 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
01Mechanism of Action
Parameter
Adipotide
MT-1
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Antibody development
—
—
02Dosage Protocols
Parameter
Adipotide
MT-1
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Route
Intravenous (systemic injection)
Subcutaneous implant — upper arm or abdomen
Frequency
Not specified in available data
Every 60 days
Sustained release implant — no daily administration required.
Evidence basis
Preclinical animal models only
Phase 3 RCT / FDA-approved orphan drug
Human data
None — no clinical trials reported
—
Standard dose
—
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
Indication
—
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
Duration
—
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
Stability
—
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
MT-1
Primary fat target
White adipose tissue (all depots)
—
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
04Side Effects & Safety
Parameter
Adipotide
MT-1
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Nausea
—
Common (>10%) — mild, transient
Implant site reaction
—
Erythema, bruising, tenderness at insertion site
Hyperpigmentation
—
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
Melanocytic changes
—
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
Headache
—
Occasional (MC1R-independent melanocortin effects)
Photosensitivity (paradoxical)
—
Rare phototoxic reactions despite melanin increase
Contamination risk (unregulated)
—
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
05Administration Protocol
Parameter
Adipotide
MT-1
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
5. Monitoring
—
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.